MedTrace Logo

A Study to Determine the Efficacy and Safety of 122-0551 in Subjects With Plaque Psoriasis

NCT01700985 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2018-10-25

Study results available
· View outcomes & findings →

Summary

Corticosteroids are one of the mainstays of treatment for subjects with corticosteroid-responsive dermatoses such as psoriasis. This study has been designed to determine and compare the efficacy and safety of a formulation of 122-0551 versus the corresponding Vehicle in subjects with stable plaque psoriasis after twice daily dosing for 14 consecutive days.

Conditions

Interventions

DRUG

122-0551

Applied twice daily for two weeks

DRUG

Vehicle

Applied twice daily for two weeks

Sponsors & Collaborators

  • Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Syd Dromgoole, PhD · Therapeutics, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2012-09-30
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01700985 on ClinicalTrials.gov